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A lymphoepithelioma-like carcinoma (LELC) is a rare neoplasm of the urinary bladder. A 71-year-old man
presented with gross hematuria for several weeks. On cystoscopy, a solid sessile tumor was observed in
the bladder dome. A partial cystectomy was performed. Histopathological ﬁndings showed that the
lesion was a pure LELC of the urinary bladder. The patient was followed up for 24 months without tumor
recurrence. We present the case to highlight the signiﬁcance of differentiating this rare tumor and
discuss the prognosis and treatment options.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
A lymphoepithelioma is an undifferentiated epithelial carci-
noma of the nasopharynx, histologically distinct due to the
prominent lymphoid inﬁltration. Carcinomas with similar histo-
logical features arising outside the nasopharynx are called
lymphoepithelioma-like carcinomas (LELCs), which have been
described in the lungs, thymus, salivary glands, cervix, and bladder.
A primary LELC of the urinary bladder was ﬁrst reported in 1991.1 To
date, fewer than 75 cases have been reported in the literature. The
pure form of LELC is considered to have a favorable prognosis and
may respond well to chemotherapy and radiotherapy. It is impor-
tant to differentiate an LELC from a lymphoma, poorly differenti-
ated urothelial carcinoma, and poorly differentiated squamous cell
carcinomawith a lymphoplasmacytic background, because an LELC
of the urinary bladder can bemanagedwith bladder preservation in
some cases. Herein, we report a case of an LELC of the urinary
bladder in a 71-year-old man, to highlight its possibility despite its
rarity.
2. Case report
A 71-year-old man presented with intermittent painless gross
hematuria for several weeks. An initial examination withackay Memorial Hospital, 92
n.
ciation. Published by Elsevier Taiwintravenous urography (IVU) revealed a ﬁlling defect in the bladder
wall. Cystoscopy showed a 2  2 cm sessile tumor located in the
bladder dome (Fig. 1). Computed tomography (CT) of the abdomen
and pelvis showed no evidence of perivesical tumor invasion or
distant metastasis. Thus, the patient received transurethral resec-
tion (TUR) and fulguration of the bladder tumor. The histopa-
thology report showed an undifferentiated carcinoma, with lamina
propria inﬁltration. Intravesical instillation with Bacillus Calmette-
Guerin (BCG) was performed after the ﬁrst operation. However,
follow-up cystoscopy showed a recurrent bladder tumor from the
original tumor bed 6 months later. A partial cystectomy with pelvic
lymph node dissection was performed for the solitary bladder
tumor.
Histopathology showed that the tumor consisted of high-grade
tumor cells admixed with lymphoid tissue, resulting in a picture
reminiscent of a nasopharyngeal carcinoma (Fig. 2). The tumor
showed transmural inﬁltration, but no invasion of the perivesical
fat (Fig. 3). Therefore, the tumor was assessed as stage T2 disease.
Immunohistochemical studies showed that the neoplasm was
positive for cytokeratin (AE1/AE3) (Fig. 4) but negative for vimentin
(Fig. 5), high-molecular-weight cytokeratin (34bE12), cytokeratin
5/6, cytokeratin 20, and CD141. The morphologic features and the
immunoproﬁle of the tumor supported a diagnosis of a pure LELC of
the urinary bladder. The surgical margins and dissected lymph
nodes were tumor-free.
The Foley catheter was removed 2 weeks after the partial cys-
tectomy. No tumor recurrence was identiﬁed by cystoscopy per-
formed at 3, 6, 12, 18, and 24 months. CT scans showed no evidencean LLC. Open access under CC BY-NC-ND license.
Fig. 1. Cystoscopy showed a sessile, protruding tumor arising from the dome of the
urinary bladder (arrow).
Fig. 3. Syncytial pattern of high-grade tumor cells with prominent nucleoli admixed
with lymphoid tissue. Most tumor cells have vesicular nuclei, distinctive nucleoli, and
indistinctive cell borders (arrow, H&E stain, 400).
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currently alive and free of disease.3. Discussion
An LELC of the urinary bladder is an extremely rare tumor ﬁrst
described by Zukerberg et al in 1991.1 In 1994, Amin et al catego-
rized LELCs of the urinary bladder into three subgroups: pure,
predominant (>50% lymphoepithelial component), and focal
(<50% lymphoepithelial component).2 To date, fewer than 75 cases
have been reported.3 The largest study was by Porcaro et al, who
pooled 43 cases from several sources.4 According to their pooled
analysis, an LELC of the urinary bladder is a male-predominant
tumor with a male-to-female ratio of 3:1. The average age was
68.4 (52e84) years. Most patients present with painless grossFig. 2. Pleomorphic tumor cells have invaded the muscle layer of the bladder wall
(H&E stain, 200).hematuria. During a mean follow-up of 37.7 months, the disease-
speciﬁc overall survival was 71%. It was noteworthy that survival
of the pure and predominant forms of LELC of the urinary bladder
was >90%. Most previous studies suggested that patients with an
LELC, especially of the pure and predominant forms, have a rela-
tively better prognosis compared to patients with a stage-matched
urothelial carcinoma. An intense immunological response by inﬁl-
trating lymphoid cells against the tumor may play an important
role.2 Moreover, inﬂammatory inﬁltration may cause early symp-
toms, such as gross hematuria, frequency, and urgency, which
should promptly alert patients.
The Epstein-Barr virus (EBV) is sometimes associated with
a lymphoepithelioma of the nasopharynx, but EBV was not
detected in any of the cases of LELC of the urinary bladder.5,6
Increased expression of the p53 protein, which is not related to
the p53 mutation, was demonstrated.7 Histopathological features
of LELCs closely resemble those of lymphoepitheliomas of theFig. 4. Positive cytokeratin (AE1/AE3) immunostaining of tumor cells, indicating an
epithelial origin (CK stain, 200).
Fig. 5. Negative vimentin (a marker of sarcoma) staining of tumor cells (vimentin
stain, 200).
Table 1
Classiﬁcation of urothelial neoplasms.
I. Urothelial neoplasms
A. Benign
B. Papillary urothelial neoplasm of low malignant potential
C. Malignant
i. Papillarya
a. Typical
b. Micropapillary
ii. Nonpapillary
a. Carcinoma in situ
b. Microinvasive carcinoma
c. Frankly invasive carcinoma
II. Undifferentiated carcinomasb
A. Small-cell carcinoma
B. Large-cell neuroendocrine carcinoma
C. Lymphoepithelioma-like carcinoma
D. Osteoclast-rich carcinoma
E. Giant-cell carcinoma
F. Otherwise unspeciﬁed
a Papillary tumors may be invasive or noninvasive.
b Tumors that are undifferentiated by light microscopy. Table modiﬁed from
Amin (2009).3
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large undifferentiated malignant epithelial cells within a dense
inﬂammatory background. Tumor cells have large vesicular nuclei
with prominent nucleoli and scant cytoplasm. The differential
diagnosis includes poorly differentiated squamous cell carcinoma,
small-cell carcinoma of the urinary bladder, and a lymphoma.
Immunohistochemical studies for cytokeratin and lymphoid
markers can help in resolving the differential diagnosis. Identi-
ﬁcation of epithelial markers, such as epithelial membrane
antigen (EMA) and several cytokeratins (AE1/AE3, CK7, and CK8),
can conﬁrm the epithelial origin of the LELC and exclude a diag-
nosis of a lymphoma. LELCs of the urinary bladder are typically
negative or focally positive for CK20. In contrast, a traditional
urothelial carcinoma may show high positivity for CK20.4,8
Vimentin, a protein found especially in connective tissues, is
used as a sarcoma tumor marker. Negative staining for vimentin
can exclude a diagnosis of a sarcoma. A poorly differentiated
urothelial carcinoma with lymphoid inﬁltrate is another differ-
ential diagnosis that should be considered. However, urothelial
carcinomas are typically positive for cytokeratin 20, high-
molecular-weight cytokeratin (34bE12), and CD141.3 In our
patient, the initial pathological analysis from TUR showed an
undifferentiated carcinoma, which was negative for CD141,
prostate-speciﬁc antigen, and prostatic acid phosphatase. The
ﬁnal diagnosis of an LELC was conﬁrmed, after complete tumor
resection, by the histological pattern and immunohistochemistry,
which showed that the tumor was positive for cytokeratin (AE1/
AE3) (Fig. 4) and negative for vimentin (Fig. 5), high-molecular-
weight cytokeratin (34bE12), cytokeratin 5/6, cytokeratin 20,
and CD141. According to the 2004 World Health Organization
classiﬁcation (Table 1), undifferentiated carcinomas are a cate-
gory including small-cell carcinoma, large-cell neuroendocrine
carcinoma, lymphoepithelioma-like carcinoma, osteoclast-rich
carcinoma, giant-cell carcinoma and otherwise unspeciﬁed
carcinomas. Because urothelial neoplasia has a pronounced
ability for divergent differentiation, it is important that surgical
pathologists be aware of this potential for multidirectional
differentiation and make a precise diagnosis.
To date, the histogenesis of atypical cells of LELCs is unknown. A
recent study by Williamson et al9 found characteristic chromo-
somal abnormalities in LELCs compared to traditional urothelial
carcinomas, using UroVysion ﬂuorescence in situ hybridization.Those ﬁndings indirectly suggest that pathogenesis of urinary
LELCs and traditional urothelial carcinomas may be similar.
Owing to limited experience, standard therapeutic approaches
for LELCs of the urinary bladder are not well established yet. In
cases of small tumors without deep invasion, TUR of the bladder
tumor with adjuvant therapy may be sufﬁcient. A partial or radical
cystectomy may be necessary in cases of large or muscle-invasive
tumors. The pure and predominant forms of LELCs may respond
well to cisplatin-based chemotherapy. Dinney et al reported
a complete response to chemotherapy and TUR of bladder tumors
in three cases of muscle-invasive LELCs, with no evidence of
recurrence after 6 years of follow-up.10 Radiotherapy and intra-
vesical chemotherapy are also used as adjuvant therapies. However,
the survival beneﬁt is not well documented, due to the limited
number of cases. Becausemost LELCs of the urinary bladder present
as solitary sessile masses and the rate of metastasis is low, bladder
preservation may be possible. However, some authors suggested
that conservative treatment should be considered only in cases of
pure or predominant LELCs.9 Our patient is well without evidence
of disease 24 months after a partial cystectomy.
In conclusion, LELCs of the urinary bladder are rare. It is
important to differentiate them from other tumors because of their
relatively favorable prognosis. Although standard treatment has
not been established, a combination of a bladder-preserving
approach and adjuvant therapy may be appropriate.
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